Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSP90-PI3K conjugate
- Development stage
- Preclinical
- Lead developer
- Tarveda Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The HSP90-PI3K conjugate is a preclinical-stage small molecule drug conjugate (SMDC) being developed by SciClone Pharmaceuticals under an exclusive license from Tarveda Therapeutics for the Greater China region. Built on Tarveda's Pentarin® miniature drug conjugate platform, the molecule consists of a heat shock protein 90 (HSP90) binding moiety linked to a phosphoinositide 3-kinase (PI3K) inhibitor payload. This dual-targeting approach leverages the selective overexpression of activated HSP90 in the tumor microenvironment to concentrate the PI3K inhibitor within cancer cells. By targeting both the HSP90 chaperone and the PI3K signaling pathway, the conjugate aims to achieve potent anti-tumor activity in solid tumors while minimizing systemic side effects typically associated with broad PI3K inhibition.
- Other names
- HSP90-PI3K small molecule conjugateHSP-90-PI3K small molecule conjugateHSP 90-PI3K small molecule conjugateHSP90-PI3K SMDCHSP-90-PI3K SMDCHSP 90-PI3K SMDC
02
Targets
HSP90 (Heat shock protein 90 chaperone complex)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on HSP90-PI3K conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSP90-PI3K conjugate.